On March 16, 2021, Solid Biosciences joined PPMD for a webinar to provide a safety and efficacy update on the ongoing IGNITE DMD phase I/II clinical study of SGT-001 microdystrophin gene therapy in patients with Duchenne muscular dystrophy. Research & Clinical Trial Webinars,Webinars 4 years ago You may also like 43:40 Webinar: Interim Results from FORWARD-53 Study of WVE-N531 in Duchenne Muscular Dystrophy 5 months ago Research & Clinical Trial Webinars,Webinars wave life sciences,WVE-N531 51:42 Webinar: Overview of DUVYZAT and Access Resources (September 2024) 6 months ago Research & Clinical Trial Webinars,Webinars 1:04:54 Webinar: Advocating for A Successful School Year (September 2024) 6 months ago Care Webinars,Webinars 1:01:24 Webinar: PPMD Advocacy – Raising Our Voices in 2024 and Beyond [Sep 2024] 6 months ago Webinars 1:00:59 Webinar: Advancing DYNE-251 – An Investigational Medicine for Duchenne to Deliver for Patients 7 months ago Research & Clinical Trial Webinars,Webinars dyne therapeutics,DYNE-251 1:05:32 Webinar: Edgewise Therapeutics – Clinical Trials in Becker Muscular Dystrophy 7 months ago Research & Clinical Trial Webinars,Webinars edgewise 58:10 Webinar: Community Progress in Duchenne Newborn Screening 10 months ago Webinars feature,newborn screening 1:01:30 Webinar: Community Update with ITF Therapeutics – Introducing DUVYZAT™ (givinostat) 12 months ago Research & Clinical Trial Webinars,Webinars duvyzat,feature,givinostat,itf therapeutics «1234…25»Page 2 of 25